<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698763</url>
  </required_header>
  <id_info>
    <org_study_id>3001088</org_study_id>
    <nct_id>NCT00698763</nct_id>
  </id_info>
  <brief_title>Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables</brief_title>
  <acronym>Electro</acronym>
  <official_title>Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables and Cerebrovascular Reactivity in Patients With Recent Stroke or TIA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to explore the safety of low doses of oral levosimendan in patients
      with recent history of an ischaemic cerebrovascular event (stroke or TIA). The main focus
      will be on the evaluation of proarrhythmic potential of the different dose regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicentre, phase II, randomized, double-blind, placebo-controlled
      2-arm parallel group study with 5 escalating dose-levels of oral levosimendan, each given for
      13-18 days. The study population will be randomly allocated either to the levosimendan group
      or to the placebo group. The double-blind phase with either placebo or levosimendan is
      preceded by a 13-day long single-blind treatment with placebo (placebo run-in). The study
      consists of 9 visits (screening visit, 7 visits during the treatment period and an
      end-of-study visit). Each subject will be on study treatment (including placebo run-in) for
      78-108 days and the duration of the study for each subject, including the screening and the
      end of study visit, is approximately 17 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-h Holter reporting</measure>
    <time_frame>every 2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Transient Ischemic Attack</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levosimendan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>from 0.125 mg to 2 mg in escalating doses</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules are identical in appearance to active capsules</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 50 to 80 years of age with ischaemic stroke or TIA within 1
             to 9 months before the screening visit.

        Exclusion Criteria:

          -  Stroke or TIA due to cardiac embolism, vasculitis or arterial dissection

          -  Severe hemiparesis or dysphasia, haemodynamically significant uncorrected valve
             disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy, any acute
             coronary event or angioplasty or any other major surgery within 1 month, any major
             surgery during the planned study period

          -  History of life-threatening ventricular arrhythmia within 3 months.

          -  History of Torsades de Pointes (TdP) or family history of long QT-syndrome

          -  Heart rate (HR) &lt; 50 or &gt; 100 bpm.

          -  Systolic blood pressure (SBP) &lt; 100 mmHg or &gt; 180 mmHg, or diastolic blood pressure
             (DBP) &gt; 100 mmHg.

          -  Ventricular tachycardia.

          -  Episode of atrial fibrillation or atrial flutter lasting &gt; 60 seconds.

          -  Second or third degree atrioventricular (AV) block.

          -  Potassium (K) &lt; 3.7 mmol/l or &gt; 5.5 mmol/l.

          -  Creatinine &gt; 170 µmol/l or on dialysis.

          -  Blood haemoglobin &lt;10 g/dl; clinically significant hepatic impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irja Korpela</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Risto O. Roine, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital (HUCH)</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital (TYKS)</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Clinic</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debrecen University</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Dept of Neurology</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Neurologmottagningen</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital, Strokecenter NVS</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Juha Ellmen, Clinical Program Leader</name_title>
    <organization>Orion Pharma</organization>
  </responsible_party>
  <keyword>An ischaemic cerebrovascular event (stroke or TIA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

